The estimated Net Worth of Scott M. Giacobello is at least $2.8 Milion dollars as of 26 February 2021. Mr. Giacobello owns over 155,448 units of GW Pharmaceuticals stock worth over $11,789 and over the last 6 years he sold GWPH stock worth over $53,838. In addition, he makes $2,731,500 as Chief Financial Officer at GW Pharmaceuticals.
Sign up
Mr. Giacobello GWPH stock SEC Form 4 insiders trading
Scott has made over 7 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 155,448 units of GWPH stock worth $10,881 on 26 February 2021.
The largest trade he's ever made was exercising 155,448 units of GW Pharmaceuticals stock on 26 February 2021 worth over $10,881. On average, Scott trades about 25,322 units every 61 days since 2019. As of 26 February 2021 he still owns at least 168,408 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Giacobello stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Giacobello biography
Scott Giacobello serves as Chief Financial Officer of the Company. Scott Giacobello has served as our Chief Financial Officer since March 2017. Mr. Giacobello has over 25 years of finance and operational experience. He is an accomplished executive who most recently served as chief financial officer for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, most recently serving as Vice President of Finance for Global Research & Development. While at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. Mr. Giacobello’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a Certified Public Accountant.
What is the salary of Scott Giacobello?
As the Chief Financial Officer of GW Pharmaceuticals, the total compensation of Scott Giacobello at GW Pharmaceuticals is $2,731,500. There are 4 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is Scott Giacobello?
Scott Giacobello is 49, he's been the Chief Financial Officer of GW Pharmaceuticals since 2017. There are 12 older and no younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Scott Giacobello's mailing address?
Scott's mailing address filed with the SEC is SOVEREIGN HOUSE, VISION PARK, HISTON, , CAMBRIDGE, X0, CB24 9BZ.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble oraz Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. Giacobello stock trades at GW Pharmaceuticals
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America